Pfizer’s lucrative launch portfolio will drive long-term revenue growth.
By Ali Al-Bazergan, Lead Analyst
26 April 2016
I am the Lead Analyst of the company analysis team at Datamonitor Healthcare, based in the London office. I focus on tra...
Read full bio
Between 2015 and 2025, sales from Pfizer’s prescription pharmaceutical revenues are forecast to grow by $809m. Tailwinds from the launch of a number of promising late-stage candidates will drive revenue expansion countering generic exposure to historically successful brands. Pfizer’s oncology portfolio is expected to be the company’s main growth driver due to momentum from the company’s breast cancer drug Ibrance (palbociclib), its non-small cell lung cancer drug Xalkori (crizotinib) and its Phase III immuno-oncology candidate avelumab partnered with Merck KGaA. Pfizer will also be buoyed by its Prevnar franchise, currently the best-selling vaccine worldwide and is expected to maintain its leading position during the forecast period. After terminating its merger with Allergan, Pfizer will now look towards a decision to separate its innovative and established business by the end of 2016 while continuing to pursue attractive business development. Datamonitor Healthcare expects Pfizer to leverage its financial capacity by targeting companies that will support the growth trajectory of its innovative pharmaceuticals business.
Pfizer’s therapy area dynamics, 2015–25
Datamonitor Healthcare’s company analysis on Pfizer explores global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Get your free demo today – simply fill out the form to the right.